Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Xencor, Inc.
Nuvectis Pharma, Inc.
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
Takeda
Kidney Cancer Research Bureau
Second Life Therapeutics
Novartis
Kura Oncology, Inc.
AstraZeneca
Dana-Farber Cancer Institute
Coherus Oncology, Inc.
Virginia Commonwealth University
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
7 Hills Pharma, LLC
A2 Biotherapeutics Inc.
Washington University School of Medicine
Genentech, Inc.
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
DEKA Biosciences
Columbia University
Memorial Sloan Kettering Cancer Center
Elevation Oncology
Centre Georges Francois Leclerc
Rutgers, The State University of New Jersey
Nimbus Therapeutics
Astellas Pharma Inc
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
Inhibrx Biosciences, Inc
Hospices Civils de Lyon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Cedars-Sinai Medical Center
Celldex Therapeutics
AO GENERIUM
Aurigene Discovery Technologies Limited
Corvus Pharmaceuticals, Inc.
Barbara Ann Karmanos Cancer Institute
Canadian Cancer Trials Group
Kineta Inc.
AvenCell Therapeutics, Inc.
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Imperial College London
Roswell Park Cancer Institute